Does Semax help with recovery after a stroke?
Yes. Semax has significant clinical evidence in humans supporting its use for ischemic stroke recovery. This makes Semax the single best-established use in the entire published research base. Unlike many other uses discussed elsewhere, stroke recovery is an area where Semax actually has real clinical trial data behind it. This is not just theoretical mechanisms or animal studies.
In a study of 110 patients after ischemic stroke—a stroke caused by a blocked blood vessel cutting off oxygen supply to a part of the brain—Semax significantly increased plasma BDNF levels. This occurred regardless of when rehabilitation began. These elevated BDNF levels correlated directly with better outcomes on the Barthel scale, a standard measure of a patient's ability to perform daily activities independently. They also correlated with faster improvement in motor function [1]. This is actual human outcome data and not an extrapolation from animal models.
A prior clinical study analyzed 30 patients in the acute phase after an ischemic stroke in the cerebral hemisphere. Researchers compared them with 80 control patients receiving conventional therapy only. The Semax group showed accelerated recovery of damaged neurological functions. Doses of 12 milligrams per day for moderate strokes and 18 milligrams per day for severe strokes were deemed most effective. Treatment courses lasted 5–10 days [2]. This study also included objective monitoring—EEG mapping and somatosensory evoked potentials, which measure the speed of sensory signal processing by the brain. This confirmed that clinical improvements translated into measurable changes in brain function, not just subjective assessment [2].
What does research say about how Semax helps with stroke recovery?
Researchers have meticulously mapped the mechanisms behind Semax's benefits in stroke at the molecular level. They used rat models with temporarily blocked cerebral arteries, closely mimicking human ischemic stroke.
RNA sequencing analysis revealed something significant. Semax suppressed the activity of inflammation-related genes that stroke pathologically turned on. Simultaneously, it restored the activity of neurotransmission-related genes that stroke suppressed [3]. This dual action—calming harmful post-stroke inflammation while restoring normal brain signaling—appears in subsequent studies using different methods. One genome-wide analysis showed that immune response was the single most affected biological process under Semax treatment post-stroke [4].
At the protein level, Semax increased active CREB. CREB is a protein central to the transformation of brain activity into lasting regeneration and memory processes. This increase occurred specifically in the stroke-affected area. Simultaneously, Semax decreased MMP-9, c-Fos, and active JNK – all markers associated with cell death and tissue damage in the surrounding brain tissue [5]. Semax also altered the activity of the VEGF gene family, which controls the formation and repair of blood vessels. These effects specifically counteracted the harmful vascular disruption caused by the stroke itself [6].
In a clinical study of stroke patients, Semax shifted the balance of inflammatory markers toward an anti-inflammatory profile. It increased interleukin-10 while decreasing C-reactive protein, a marker of ongoing inflammation [7]. This directly links the molecular mechanisms seen in animal studies with what is actually happening in human stroke patients.
Does Semax help with traumatic brain injury?
Direct evidence for Semax specifically in traumatic brain injury is more limited than for ischemic stroke. However, related injury models provide significant supporting data.
In one model, researchers induced a localized brain injury in the prefrontal cortex using a technique called photothrombosis. This injury resembles focal traumatic injury in some respects. Chronic nasal Semax fully restored spatial learning ability that had been impaired by the injury. This recovery persisted long after the treatment period concluded [8]. In a related model of experimental cortical injury, Semax reduced the volume of brain lesions and improved memory performance [9].
Research into spinal cord injury offers a different perspective. It is a different, yet mechanistically linked, type of central nervous system injury. Semax induced significant functional recovery here. It improved standardized motor and coordination outcomes in injured animals. The mechanism involved reduced cell death and decreased oxidative stress [10].
These studies do not directly test Semax in a classic traumatic brain injury model. However, the consistent pattern of neuroprotection and functional recovery across multiple injury types provides a reasonable basis for interest in TBI applications. Dedicated TBI studies have simply not been published yet.
Does Semax help with postoperative cognitive decline or anesthetic effects?
No published studies have directly tested Semax for postoperative cognitive impairment or recovery from anesthesia. This is a true gap in current research.
However, the known mechanisms of Semax are relevant here. These include reducing inflammation, protecting against oxidative stress, and supporting the production of neurotrophic factors. All three processes are considered underlying postoperative cognitive changes, increasingly linked to inflammatory and oxidative responses to surgery and anesthesia. Until dedicated research is conducted in this specific context, any use of Semax for cognitive support after anesthesia remains speculative and unsupported by direct evidence.
What is the clinical picture of Semax and stroke?
Semax stands out in the broader literature on Semax. Stroke and cerebrovascular disease represent the areas with the most significant, most consistent, and most clinically relevant available human evidence.
Beyond the already discussed studies, a clinical study of 187 patients with cerebrovascular insufficiency—a condition involving chronically reduced blood flow to the brain—showed significant results. Semax treatment resulted in significant clinical improvement. It stabilized the progression of the disease. It reduced the risk of recurrent stroke and transient ischemic attacks. And it demonstrated good tolerability even in elderly patients [11].
This body of evidence includes acute stroke treatment, rehabilitation, and prevention of further cerebrovascular events. It represents the strongest and most clinically relevant application of Semax currently documented in the scientific literature.
Does Semax help with Alzheimer's disease?
Evidence for Semax in Alzheimer's disease is promising, but remains entirely preclinical. To date, no clinical trials have been conducted in humans with Alzheimer's patients.
The most direct evidence comes from a 2025 study using transgenic mice—mice genetically engineered to develop amyloid plaques similar to those seen in human Alzheimer's disease. In this model, both Semax and a peptide derivative improved cognitive function. This was demonstrated in multiple behavioral tests, including the open field test, novel object recognition, and the Barnes maze. Microscopic examination of brain tissue revealed that both peptides reduced the number of amyloid plaque deposits in the cortex and hippocampus [12].
A separate line of research analyzed the direct chemical interaction of Semax with beta-amyloid, the protein that forms Alzheimer's plaques. Semax inhibited copper-induced beta-amyloid aggregation. It interfered with the formation of toxic amyloid fibrils in artificial membrane models [13]. Copper plays a significant role in Alzheimer's pathology. It catalyzes harmful oxidative reactions when bound to beta-amyloid. Semax was found to chelate copper from these toxic copper-amyloid complexes. This reduced the harmful free radical production that this copper-amyloid interaction normally generates. Semax also demonstrated protective effects against copper-induced cell death in laboratory nerve cells [14].
Does Semax help with dementia more broadly?
Beyond amyloid-specific mechanisms relevant to Alzheimer's, Semax's broader neuroprotective profile is mechanistically relevant to dementia generally. This includes increases in BDNF and NGF, protection of cholinergic neurons — the acetylcholine-producing nerve cells crucial for memory — and antioxidant activity. These are some of the biological systems most consistently disrupted across various forms of cognitive impairment.
Semax increased the survival of cholinergic neurons from the basal forebrain by 1.5 to 1.7 times in cell culture. It also stimulated the activity of choline acetyltransferase, the enzyme responsible for the production of acetylcholine [15]. This is particularly significant. Cholinergic neurons of the basal forebrain are among the earliest and most severely affected cell populations in Alzheimer's disease. Their loss is closely linked to the memory impairment that characterizes this condition.
Does Semax help with Parkinson's disease?
Semax has demonstrated neuroprotective effects in multiple animal models specifically engineered to mimic Parkinson's disease. Parkinson's focuses on the loss of dopamine-producing neurons in a brain region called the substantia nigra.
Researchers commonly use the neurotoxin MPTP to induce parkinsonian-like dopaminergic damage in animals. In this model, daily intranasal Semax reduced the severity of neurotoxin-induced behavioral impairments. This included reduced locomotion and exacerbated anxiety, both typical of this model [16]. A more recent study used an improved mouse model that specifically tracks the degeneration of dopamine-producing nerve fibers. Semax administered prior to MPTP treatment induced a small but statistically reliable increase in dopamine levels in the striatum. Researchers concluded that Semax acts primarily by stimulating the brain's own production of neurotrophic factors, rather than mainly acting as a direct antioxidant [17].
A separate study analyzed Semax and Selank together in rats with chemically induced parkinsonism. Neither peptide significantly affected the animals' motor activity. Selank, however, reduced anxiety levels in these parkinsonian rats. This effect had previously only been seen in healthy animals [18]. This finding suggests something interesting. The dopaminergic nigrostriatal damage characteristic of parkinsonism does not eliminate the brain's reactivity to these peptides’ emotional behavior effects—even though neither peptide reversed the major motor symptoms in this particular study.
Can Semax slow the decline in cognitive function?
Based on available mechanisms and evidence from animal models, Semax has a plausible potential to support cognitive function and slow certain aspects of cognitive decline. However, this has not been directly tested in humans experiencing age-related cognitive decline or diagnosed neurodegenerative diseases.
A consistent theme runs through animal research on Alzheimer's and Parkinson's. Increased BDNF and NGF. Antioxidant protection. Reduction of neuroinflammation. Support for vulnerable neuron populations, such as cholinergic neurons of the basal forebrain and dopaminergic neurons of the substantia nigra. Together, these support the biological plausibility of Semax as a cognitive decline slowing agent.
Being biologically plausible based on animal models is significantly different from being clinically proven to slow cognitive decline in humans. No study has yet bridged this gap.
What is the full evidence base for Semax neuroprotection?
Semax's neuroprotective profile is supported by an exceptionally broad and mechanistically diverse body of research. It spans ischemic stroke, spinal cord injury, focal cortical injury, Parkinson's models, Alzheimer's models, glutamate excitotoxicity, and oxidative stress across multiple cell types and injury paradigms.
This breadth is truly remarkable. Few research compounds have been tested across as many distinct injury models with such mechanistic consistency of outcomes. The hierarchy of evidence assigns the strongest confidence to findings concerning ischemic stroke, encompassing real-world human clinical trial data [1], [2], [7], [11]. Findings for Alzheimer's, Parkinson's, and spinal cord injury remain at the animal study stage.
What are the main neuroprotective mechanisms of Semax?
Semax protects neurons through several interconnected mechanisms working together, rather than a single pathway.
The most consistently documented mechanism is the increase in neurotrophic factors. Increases in BDNF and NGF support neuron survival, growth, and the resilience of neural circuits under stress [19]. The second major mechanism is anti-inflammatory gene regulation. Genome-wide RNA sequencing studies show that Semax suppresses the activity of inflammatory genes activated by brain injury, while restoring the activity of genes needed for normal neural signaling [3], [4].
The third mechanism is antioxidant activity. This is manifested in several ways. Semax prevents excessive production of nitric oxide and lipid peroxidation following cerebral ischemia [20]. It directly chelates—binds and removes—copper ions which would otherwise catalyze harmful oxidative reactions [14]. And it protects cells exposed to oxidative stress induced by hydrogen peroxide [21].
The fourth mechanism involves calcium and mitochondrial protection. Semax delayed calcium overload and mitochondrial dysfunction, which occur during glutamate-induced excitotoxicity—a type of nerve cell damage caused by excessive stimulation. This improved neuronal survival by approximately 30% in cultured cerebellar cells under this type of toxic stress [22].
The fifth mechanism concerns vascular support. Semax modulates the expression of genes in the VEGF family [6], genes that control blood vessel formation. It also improves erythrocyte deformability – the ability of red blood cells to squeeze through narrow vessels – which enhances blood flow through narrow cerebral capillaries [23].
Finally, a newly identified mechanism involves the μ-opioid receptor pathway. Spinal cord injury research has revealed that Semax promotes a cellular process called deubiquitination. This stabilizes lysosomal membranes and reduces a specific form of inflammatory cell death called pyroptosis [10]. This adds a newly discovered molecular mechanism to an already significant list.
What do studies show about Semax and oxidative stress specifically?
Evidence for oxidative stress in Semax includes several distinct experimental approaches. All of them consistently point in the same protective direction.
In global brain ischemia models, Semax prevented an approximately twofold increase in nitric oxide production, which typically occurs after this type of injury. Glycine, tested in the same study for comparison, showed no such protective effect [20]. This is a significant finding. It demonstrates specificity. Semax's antioxidant action is not simply a general feature shared by every neuroactive compound. It appears to reflect a true pharmacological property of this particular peptide.
In cell culture studies, Semax dose-dependently protected cultured cells from death caused by hydrogen peroxide exposure. The degree of protection depended on the timing of peptide introduction relative to the oxidative stimulus [21]. In behavioral studies, Semax counteracted learning and memory impairment caused by heavy metal exposure—specifically lead and molybdenum. It was as effective as ascorbic acid, a well-established antioxidant [24]. This provides indirect behavioral confirmation of antioxidant activity in a living animal.
What does research show on Semax and neuroinflammation specifically?
Evidence for neuroinflammation is perhaps the most accurately characterized aspect of Semax's neuroprotective profile. It is based on numerous genomewide studies conducted by the same Russian research groups over more than a decade.
The earliest of these studies revealed something striking. Over half of all genes affected by Semax in the post-stroke rat brain were immune response genes. Particularly noteworthy effects appeared on genes encoding immunoglobulins and chemokines – both types of immune signaling molecules [4]. A control study using precise gene measurement technology confirmed that Semax induced statistically significant decreases in specific pro-inflammatory signaling proteins. These included IL-1α, IL-1β, IL-6, CCL3, and CXCL2 in the ischemic rat brain [25].
More recent RNA sequencing studies have extended these findings to earlier time points post-stroke. They demonstrated that Semax and a related peptide can partially prevent the dysregulation of genes associated with inflammation and neurosignaling as early as 4.5 hours after an ischemic event [26]. This timing is clinically relevant. It falls within the therapeutic window where stroke treatment is generally most effective.
How does Semax compare to other neuroprotective compounds?
In available comparative studies, Semax was tested alongside several other neuroprotective agents. The results vary depending on the measured index.
In direct comparison with mexidol, a well-established Russian neuroprotective drug, both compounds demonstrated anti-hypoxic and anti-amnestic effects in models of cerebral ischemia. However, they followed different dose-response patterns. Mexidol exhibited a linear dose-effect relationship. Semax, instead, followed a bell-shaped curve—efficacy increased and then decreased at higher doses [27].
In a comparative analysis of PGC-1α—a key regulator of brain resistance to ischemic injury—both mexidol and Semax preserved neuron numbers and PGC-1α activity in the tissue surrounding photochemically induced brain injury. This suggests a roughly comparable neuroprotective strength between the two compounds in this specific model [28].
Compared to the new tripeptide mixture tested in one study, Semax actually showed inferior performance in several measures. This included anti-hypoxic and anti-amnesic effects. The new mixture demonstrated 1.3 to 4 times greater efficacy, depending on the specific test [29]. This is a useful reminder. Semax, while well-researched, is not necessarily the most potent neuroprotective compound available—even within the narrow category of Russian-developed peptides and small-molecule neuroprotectors.
What are the limitations of current Semax neuroprotection research?
Several important limitations should temper enthusiasm regarding Semax's neuroprotective profile. This holds true even considering a truly significant body of supporting evidence.
First, the vast majority of these studies come from a relatively small number of Russian research institutions. Independent replication by research groups outside of this network is limited. This is an important consideration for scientific certainty, regardless of how internally consistent the results may seem.
Second, while the stroke has real clinical trial data, the sample sizes—ranging from 30 to 187 patients in the available studies—are small by modern clinical trial standards. None of the published human studies employed a double-blind, placebo-controlled, large-scale design that would be required for regulatory approval in most Western countries.
Thirdly, applications in Alzheimer's, Parkinson's, and traumatic brain injury remain entirely at the animal research stage. No human trials have been conducted for these specific conditions.
Fourth, most mechanistic studies use young, healthy animals, not older animals with additional health conditions. Real human patients experiencing these neurodegenerative diseases in clinical practice are more akin to the latter group.
Addressing these limitations through modern, rigorously controlled human studies would significantly strengthen the arguments for Semax's neuroprotective applications. It would also help clarify which specific patient populations and conditions are most likely to benefit.
Disclaimer
This content is for educational and scientific informational purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Semax remains a research compound in most countries, including the United States and most European countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. The strongest evidence in humans pertains specifically to ischemic stroke and cerebrovascular disease. Evidence for Alzheimer's disease, Parkinson's disease, and traumatic brain injury remains entirely preclinical, with no published human studies in these specific conditions. Additional well-designed, large-scale clinical trials are essential to confirm these preclinical findings in humans. Any individual with a neurological condition should consult with a qualified healthcare professional and should not change, discontinue, or substitute any prescribed treatment without medical guidance.
References
[1] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[3] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan'kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[4] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: Genome-wide transcriptional analysis. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[5] Sudarkina, O. Yu., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[6] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2013). Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain. Journal of Molecular Neuroscience, 49(2), 328–333. https://doi.org/10.1007/s12031-012-9853-y
[7] Miasoedova, N. F., Skvortsova, V. I., Nasonov, E. L., Zhuravleva, E. Yu., Grivennikov, I. A., Arsen’eva, E. L., & Sukhanov, I. I. (1999). Investigation of mechanisms of neuroprotective effect of semax in the acute phase of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 99(5), 15–19. PMID: 10358912
[8] Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischemic lesions to the prefrontal cortex. Neuroscience & Biobehavioral Reviews(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[9] Romanova, G. A., Silachev, D. N., Shakova, F. M., Kvashennikova, Yu. N., Viktorov, I. V., Shram, S. I., & Myasoedov, N. F. (2006). Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine, 142(6), 663-666. https://doi.org/10.1007/s10517-006-0445-0
[10] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[11] Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
Radchenko, A. I., Kuzubova, E. V., Apostol, A. A., Mitkevich, V. A., Andreeva, L. A., Limborska, S. A., Stepenko, Yu. V., Shmigerova, V. S., Solin, A. V., Korokin, M. V., Pokrovskii, M. V., Myasoedov, N. F., & Makarov, A. A. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 17(4), 110–120. https://doi.org/10.32607/actanaturae.27808
[13] Sciacca, M. F. M., Naletova, I., Giuffrida, M. L., & Attanasio, F. (2022). Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience, 13(4), 486–496. https://doi.org/10.1021/acschemneuro.1c00707
[14] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[15] Grivennikov, I. A., Dolotov, O. V., Zolotarev, Yu. A., Andreeva, L. A., Myasoedov, N. F., Leacher, L., Black, I. B., & Dreyfus, C. F. (2008). Effects of behaviorally active ACTH(4-10) analogue — Semax on rat basal forebrain cholinergic neurons. Restorative Neurology and Neuroscience, 26(1), 35–43. PMID: 18431004
Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioral Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
Kolacheva, A. A., & Ugrumov, M. V. (2021). A mouse model of nigrostriatal dopaminergic axonal degeneration as a tool for testing neuroprotectors. Acta Naturae, 13(3), 110–113. https://doi.org/10.32607/actanaturae.11433
[18] Slominsky, P. A., Shadrina, M. I., Kolomin, T. A., Stavrovskaya, A. V., Filatova, E. V., Andreeva, L. A., Illarioshkin, S. N., & Myasoedov, N. F. (2017). Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady Biological Sciences, Vol. 474(1), 106-109. https://doi.org/10.1134/S0012496617030048
[19] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[20] Bashkatova, V. G., Koshelev, V. B., Fadyukova, O. E., Alexeev, A. A., Vanin, A. F., Rayevsky, K. S., Ashmarin, I. P., & Armstrong, D. M. (2001). Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Research, 894(1), 145–149. https://doi.org/10.1016/s0006-8993(00)03324-2
[21] Safarova, E. R., Shram, S. I., Zolotarev, Yu. A., & Myasoedov, N. F. (2003). Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress. Bulletin of Experimental Biology and Medicine, 135(3), 268–271. https://doi.org/10.1023/a:1024141232307
Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of Semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
Semax increases erythrocyte deformability in the shearing blood stream in intact rats and rats with cerebral ischemia. Doklady Biological Sciences, 439, 208–211. https://doi.org/10.1134/S0012496611040168
[24] Inozemtsev, A. N., Bokieva, S. B., Karpukhina, O. V., Gumargalieva, K. Z., Kamensky, A. A., & Myasoedov, N. F. (2016). Semax prevents learning and memory inhibition by heavy metals. Doklady Biological Sciences, 468(1), 112–114. https://doi.org/10.1134/S0012496616030066
Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[26] Filippenkov, I. B., Remizova, J. A., Stavchansky, V. V., Denisova, A. E., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2023). Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes, 14(7), 1382. https://doi.org/10.3390/genes14071382
[27] Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of mexidol and semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550
[28] Shakova, F. M., Kirova, Yu. I., Silachev, D. N., Romanova, G. A., & Morozov, S. G. (2021). Protective effects of PGC-1α activators on ischemic stroke in a rat model of photochemically induced thrombosis. Brain Sciences, 11(3), 325. https://doi.org/10.3390/brainsci11030325
[29] Iasnetsov, V. V., Chertorizhskiĭ, E. A., Belyĭ, P. A., Bespalova, Zh. D., Ovchinnikov, M. V., Vereshchagina, A. O., Ivanov, Yu. V., Iasnetsov, Vik. V., Kirsanova, S. K., & Motin, V. G. (2015). Study of neuroprotective, antihypoxic, and antiamnesic effects of a new mixture of tripeptides. Experimental and Clinical Pharmacology, 78(1), 3–8. PMID: 25826866